Guanidino Compounds as Cause of Cardiovascular Damage in Chronic Kidney Disease: An in vitro Evaluation

被引:53
作者
Schepers, Eva [1 ]
Glorieux, Griet [1 ]
Dou, Laetitia [2 ]
Cerini, Claire [2 ]
Gayrard, Nathalie [3 ,4 ]
Louvet, Loic [5 ]
Maugard, Charlotte [5 ]
Preus, Pierre [6 ]
Rodriguez-Ortiz, Maria [7 ]
Argiles, Angel [3 ,4 ]
Brunet, Philippe [2 ]
Cohen, Gerald [8 ,9 ]
Jankowski, Joachim [6 ]
Jankowski, Vera [6 ]
Massy, Ziad [5 ]
Rodriguez, Mariano [7 ]
Vanholder, Raymond [1 ]
机构
[1] Ghent Univ Hosp, Dept Internal Med, Div Nephrol, BE-9000 Ghent, Belgium
[2] Aix Marseille Univ Marseille, INSERM, UMR 608, Marseille, France
[3] SAS RD Nephrol, Montpellier, France
[4] Inst Funct Genom, Montpellier, France
[5] Univ Picardie Jules Verne, Amiens Univ Hosp, INSERM, ERI 12, Amiens, France
[6] Charite, Med Klin 4, D-13353 Berlin, Germany
[7] Univ Hosp Reina Sofia, Serv Nephrol, Unidad Invest, REDinREN, Cordoba, Spain
[8] Med Univ Vienna, Div Nephrol & Dialysis, Vienna, Austria
[9] Med Univ Vienna, Dept Med 3, Vienna, Austria
关键词
Atherosclerosis; Chronic kidney disease; Guanidino compounds; SDMA; Uremic toxins; Vascular damage; CHRONIC-RENAL-FAILURE; UREMIC RETENTION SOLUTES; CORONARY-ARTERY-DISEASE; SOLUBLE L-SELECTIN; ASYMMETRICAL DIMETHYLARGININE; DIALYZED PATIENTS; P-CRESOL; HEMODIALYSIS; PLASMA; MORTALITY;
D O I
10.1159/000320765
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Chronic kidney disease is considered a major cause of cardiovascular risk and non-traditional risk factors remain largely unknown. The in vitro toxicity of 10 guanidino compounds (GCs) was evaluated via a standardized approach on different cell systems of relevance in cardiovascular disease. The parameters evaluated were production of reactive oxygen species, expression of surface molecules, cell proliferation, cytotoxicity and calcification. Several GCs had a stimulatory effect on monocytes and granulocytes (SDMA, creatine and guanidinobutyric acid (GBA)). Some GCs (guandine (G), guanidinosuccinic acid (GSA) and SDMA) inhibited endothelial cell proliferation or reduced calcification in osteoblast-like human VSMC (ADMA, GSA and SDMA). Stimulation of osteoclastogenesis could be demonstrated for ADMA, G, guanidinoacetic acid and GBA in a RAW264.7 cell line. No compounds were cytotoxic to AoSMC or endothelial cells, nor influenced their viability. GCs, especially SDMA, likely contribute to cardiovascular complications in uremia, mainly those related to microinflammation and leukocyte activation. Copyright (C) 2010 S. Karger AG, Basel
引用
收藏
页码:277 / 287
页数:11
相关论文
共 49 条
[1]   Symmetrical dimethylarginine:: A new combined parameter for renal function and extent of coronary artery disease [J].
Bode-Boeger, Stefanie M. ;
Scalera, Fortunato ;
Kielstein, Jan T. ;
Martens-Lobenhoffer, Jens ;
Breithardt, Guenter ;
Fobker, Manfred ;
Reinecke, Holger .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2006, 17 (04) :1128-1134
[2]  
Caimi G, 2005, CLIN HEMORHEOL MICRO, V32, P43
[3]   Review on uraemic toxins III:: recommendations for handling uraemic retention solutes in vitro -: towards a standardized approach for research on uraemia [J].
Cohen, Gerald ;
Glorieux, Griet ;
Thornalley, Paul ;
Schepers, Eva ;
Meert, Natalie ;
Jankowski, Joachim ;
Jankowski, Vera ;
Argiles, Angel ;
Anderstam, Bjorn ;
Brunet, Philippe ;
Cerini, Claire ;
Dou, Laetitia ;
Deppisch, Reinhold ;
Marescau, Bart ;
Massy, Ziad ;
Perna, Alessandra ;
Raupachova, Jana ;
Rodriguez, Mariano ;
Stegmayr, Bernd ;
Vanholder, Raymond ;
Horl, Walter H. .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2007, 22 (12) :3381-3390
[4]   Asymmetrical dimethylarginine - The Uber marker? [J].
Cooke, JP .
CIRCULATION, 2004, 109 (15) :1813-1818
[5]   Prevalence of chronic kidney disease in the United States [J].
Coresh, Josef ;
Selvin, Elizabeth ;
Stevens, Lesley A. ;
Manzi, Jane ;
Kusek, John W. ;
Eggers, Paul ;
Van Lente, Frederick ;
Levey, Andrew S. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (17) :2038-2047
[6]   Endogenous guanidino compounds as uremic neurotoxins [J].
De Deyn, PP ;
D'Hooge, R ;
Van Bogaert, PP ;
Marescau, B .
KIDNEY INTERNATIONAL, 2001, 59 :S77-S83
[7]   GUANIDINO COMPOUNDS IN UREMIC DIALYZED PATIENTS [J].
DEDEYN, P ;
MARESCAU, B ;
LORNOY, W ;
BECAUS, I ;
LOWENTHAL, A .
CLINICA CHIMICA ACTA, 1986, 157 (02) :143-150
[8]   GUANIDINO COMPOUND LEVELS IN BRAIN-REGIONS OF NON-DIALYZED UREMIC PATIENTS [J].
DEDEYN, PP ;
MARESCAU, B ;
DHOOGE, R ;
POSSEMIERS, I ;
NAGLER, J ;
MAHLER, C .
NEUROCHEMISTRY INTERNATIONAL, 1995, 27 (03) :227-237
[9]   GUANIDINO COMPOUNDS IN SERUM AND CEREBROSPINAL-FLUID OF NON-DIALYZED PATIENTS WITH RENAL-INSUFFICIENCY [J].
DEDEYN, PP ;
MARESCAU, B ;
CUYKENS, JJ ;
VANGORP, L ;
LOWENTHAL, A ;
DEPOTTER, WP .
CLINICA CHIMICA ACTA, 1987, 167 (01) :81-88
[10]   Outcomes research in dialysis [J].
Dhingra, H ;
Laski, ME .
SEMINARS IN NEPHROLOGY, 2003, 23 (03) :295-305